Esperion Therapeutics (ESPR) H.C. Wainwright 26th Annual Global Investment Conference summary

Foundational growth pillars and market opportunity

• Large addressable market in cardiovascular disease, the leading global cause of death.

• Breakthrough therapies with bempedoic acid, a first-in-class drug.

• Strong global partnerships with Daiichi Sankyo and Otsuka, expanding international reach.

• Robust intellectual property protection through 2031, with potential extension strategies.

• Highly experienced leadership team with proven product launch success.

Recent achievements and growth

• Monetized European royalties, significantly reducing debt.

• Secured updated utilization management criteria, improving managed care reimbursement.

• Achieved double-digit growth in both prescriptions and total revenue in recent quarters.

• Expanded Medicare coverage to approximately 85% and commercial coverage to 90%.

• Over 133 million lives now covered under the new label.

CLEAR Outcomes study and label expansion

• CLEAR Outcomes study included 14,000 patients across 32 countries, with significant media impact.

• First and only non-statin therapy with both primary and secondary prevention indications.

• New label increased total addressable market from 10 million to 70 million patients.

• Label changes removed previous prescription hurdles, simplifying access for physicians.

• Payers quickly adopted the new label, with most commercial and Medicare plans updating criteria.